JBCRG-C05｜Clinical Trials｜Japan Breast Cancer Research Group

JBCRG-C05: Cohort study evaluating efficacy of bevacizumab plus paclitaxel in patients with HER2-negative inoperable or metastatic breast cancer(JBCRG-C05)

Objectives: The purpose of this study is to evaluate the efficacy and safety of bevacizumab combined with paclitaxel as first or second line chemotherapy in clinical practice in HER2 negative inoperable or metastatic breast cancer patients.

Endpoints: Primary outcomes: Overall Survival(OS) Secondary outcomes: Response Rate(RR), Progression Free Survival(PFS), Safety

Lead Principal Investigator: 1)Yutaka Yamamoto,Kumamoto University Hospital 2)Hiroyasu Yamashiro, National Hospital Organization Kure Medical Center and Chugoku Cancer Center

Conference Presentation: Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE) Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)

Articles and Publications: Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies Breast Cancer Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

Clinical Trials